B+
Bull case
25%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
OFIX
Orthofix MedicalANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-04
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+92.5
Score
AI commentary
Recent news is constructive around Q2 execution and raised guidance, but coverage is low, social coverage is unavailable, analyst target breadth is unavailable, and no reliable options or employee-sentiment data are provided. This supports a cautious monitoring view rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-09-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 operating progress and raised FY2026 guidanceMedium impact
Q2 net sales rose 4% reported and 5% pro forma constant currency, with double-digit growth in Global Spine Fixation and Global Limb Reconstruction; management also raised FY2026 net sales and adjusted EBITDA guidance. [#SEC-8K-2026-08-05]
2026-09-30catalystProfitability and cash-generation scrutinyHigh impact
Q2 included a $15.8 million GAAP net loss, adjusted EBITDA of $20.1 million versus $20.6 million year over year, and lower cash partly due to arbitration and settlement payments. [#SEC-8K-2026-08-05]
2026-12-31catalystMedicare reimbursement restoration supports Therapeutic SolutionsHigh impact
Restoration of Medicare reimbursement for non-invasive bone growth stimulators removes a stated second-half headwind, but execution and demand recovery remain to be demonstrated. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-04 • Updated nightlySource: Internal modelMethodology